Evidence map›Paper›PMID 38492217›Full record

ArticleCell reports2024

Interaction between host G3BP and viral nucleocapsid protein regulates SARS-CoV-2 replication and pathogenicity.

Zemin Yang, Bryan A Johnson, Victoria A Meliopoulos, Xiaohui Ju, Peipei Zhang, Michael P Hughes, Jinjun Wu, Kaitlin P Koreski, Jemma E Clary, Ti-Cheng Chang and 18 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Pharmacological modulation of stress granulesFrontiers in pharmacology · 2026
    Review
  10. SARS-CoV-2 nsp14 induces the mCommunications biology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 3 institutions in 2 countries.

Zemin YangDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA; Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, TN, USA.
Bryan A JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA; Center for Tropical Diseases, University of Texas Medical Branch, Galveston, TX, USA.
Victoria A MeliopoulosDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Xiaohui JuSchool of Medicine, Tsinghua University, Beijing, China.
Peipei ZhangDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Michael P HughesDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jinjun WuDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA; Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, TN, USA.
Kaitlin P KoreskiDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jemma E ClaryDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Ti-Cheng ChangCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Gang WuCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jeff HixonFaze Medicines, Cambridge, MA, USA.
Jay DuffnerFaze Medicines, Cambridge, MA, USA.
Kathy WongFaze Medicines, Cambridge, MA, USA.
Rene LemieuxFaze Medicines, Cambridge, MA, USA.
Kumari G LokugamageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
R Elias AlvaradoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Patricia A Crocquet-ValdesDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
David H WalkerDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Kenneth S PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA.
Jessica A PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA.
Hong Joo KimDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Rachel MeyersFaze Medicines, Cambridge, MA, USA.
Stacey Schultz-CherryDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Qiang DingSchool of Medicine, Tsinghua University, Beijing, China.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: vimenach@utmb.edu.
J Paul TaylorDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. Electronic address: jpaul.taylor@stjude.org.
St. Jude Children's Research Hospital · USThe University of Texas Medical Branch at Galveston · USTsinghua University · CN

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4M
Virology CoreU19AI171413 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2022 to 2023
$75.0M
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
Dynamic RNA-protein assemblies and neurological diseaseR35NS097974 · NINDS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI TAYLOR, JOSEPH PAUL · 2017 to 2024
$7.2M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
NIAID NIH HHS 75N93021C00016NIAID NIH HHS R21 AI145400NIAID NIH HHS R24 AI120942NIAID NIH HHS U19 AI171413NINDS NIH HHS R35 NS097974
6 · The paper itself

Abstract

G3BP1/2 are paralogous proteins that promote stress granule formation in response to cellular stresses, including viral infection. The nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibits stress granule assembly and interacts with G3BP1/2 via an ITFG motif, including residue F17, in the N protein. Prior studies examining the impact of the G3PB1-N interaction on SARS-CoV-2 replication have produced inconsistent findings, and the role of this interaction in pathogenesis is unknown. Here, we use structural and biochemical analyses to define the residues required for G3BP1-N interaction and structure-guided mutagenesis to selectively disrupt this interaction. We find that N-F17A mutation causes highly specific loss of interaction with G3BP1/2. SARS-CoV-2 N-F17A fails to inhibit stress granule assembly in cells, has decreased viral replication, and causes decreased pathology in vivo. Further mechanistic studies indicate that the N-F17-mediated G3BP1-N interaction promotes infection by limiting sequestration of viral genomic RNA (gRNA) into stress granules.

Indexed as

COVID-19SARS-CoV-2DNA HelicasesHumansNucleocapsid ProteinsPoly-ADP-Ribose Binding ProteinsRNA, Guide, CRISPR-Cas SystemsRNA HelicasesRNA Recognition Motif ProteinsRNA, ViralVirulenceVirus ReplicationDNA HelicasesG3BP1 protein, humanNucleocapsid ProteinsPoly-ADP-Ribose Binding ProteinsRNA, Guide, CRISPR-Cas SystemsRNA HelicasesRNA Recognition Motif ProteinsRNA, ViralCP: MicrobiologyG3BPhost-pathogen interactionNTF2L domainnucleocapsid proteinSARS-CoV-2 replication and pathogenesisstress granulevRNA sequestration

Identifiers

PMID38492217
PMCPMC11044841
OpenAlexW4392859090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.